JP2022099621A - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP2022099621A JP2022099621A JP2020213485A JP2020213485A JP2022099621A JP 2022099621 A JP2022099621 A JP 2022099621A JP 2020213485 A JP2020213485 A JP 2020213485A JP 2020213485 A JP2020213485 A JP 2020213485A JP 2022099621 A JP2022099621 A JP 2022099621A
- Authority
- JP
- Japan
- Prior art keywords
- hinokitiol
- oral composition
- water
- copper
- solubility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims abstract description 114
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229930007845 β-thujaplicin Natural products 0.000 claims abstract description 57
- 239000005749 Copper compound Substances 0.000 claims abstract description 23
- 150000001880 copper compounds Chemical class 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 11
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 8
- 229940108925 copper gluconate Drugs 0.000 claims description 8
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 claims description 4
- 229940079841 sodium copper chlorophyllin Drugs 0.000 claims description 4
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 abstract description 15
- 238000009472 formulation Methods 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000551 dentifrice Substances 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000002324 mouth wash Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- -1 alkali metal salt Chemical class 0.000 description 4
- 229940099898 chlorophyllin Drugs 0.000 description 4
- 235000019805 chlorophyllin Nutrition 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 150000004699 copper complex Chemical class 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- SHVRRGGZMBWAJT-ODZAUARKSA-N (z)-but-2-enedioic acid;copper Chemical compound [Cu].OC(=O)\C=C/C(O)=O SHVRRGGZMBWAJT-ODZAUARKSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 229940122959 Glucosyltransferase inhibitor Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- RAOSIAYCXKBGFE-UHFFFAOYSA-K [Cu+3].[O-]P([O-])([O-])=O Chemical compound [Cu+3].[O-]P([O-])([O-])=O RAOSIAYCXKBGFE-UHFFFAOYSA-K 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- MGIWDIMSTXWOCO-UHFFFAOYSA-N butanedioic acid;copper Chemical compound [Cu].OC(=O)CCC(O)=O MGIWDIMSTXWOCO-UHFFFAOYSA-N 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- WMYBXRITVYIFCO-UHFFFAOYSA-N copper;2-hydroxybutanedioic acid Chemical compound [Cu].OC(=O)C(O)CC(O)=O WMYBXRITVYIFCO-UHFFFAOYSA-N 0.000 description 1
- DYROSKSLMAPFBZ-UHFFFAOYSA-L copper;2-hydroxypropanoate Chemical compound [Cu+2].CC(O)C([O-])=O.CC(O)C([O-])=O DYROSKSLMAPFBZ-UHFFFAOYSA-L 0.000 description 1
- BJYLNGGDLHKELP-UHFFFAOYSA-N copper;formic acid Chemical compound [Cu].OC=O BJYLNGGDLHKELP-UHFFFAOYSA-N 0.000 description 1
- PJBGIAVUDLSOKX-UHFFFAOYSA-N copper;propanedioic acid Chemical compound [Cu].OC(=O)CC(O)=O PJBGIAVUDLSOKX-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は、ヒノキチオールを含み、ヒノキチオールの溶解性が向上している口腔用組成物に関する。 The present invention relates to an oral composition containing hinokitiol and having improved solubility of hinokitiol.
近年、食生活の多様化等により、う蝕、歯周病等の口腔内疾患が蔓延している。う蝕及び歯周病は、硬組織又は歯周ポケット内に形成されたデンタルプラーク内の口腔内細菌が発症に大きく関与している細菌感染症である。う蝕の原因菌としては、ストレプトコッカス・ミュータンス（S.mutans）等の連鎖球菌が知られており、また、歯周病の原因菌としてはポルフィロモナス・ジンジバリス(P.gingivalis)等が知られている。そのため、口腔内を健常な状態に維持するためには、口腔内におけるこれらの病原菌数を低レベルに抑えることが重要である。 In recent years, oral diseases such as dental caries and periodontal disease have become widespread due to the diversification of eating habits. Caries and periodontal disease are bacterial infections in which oral bacteria in dental plaques formed in hard tissues or periodontal pockets are largely involved in the onset. Streptococci such as Streptococcus mutans (S. mutans) are known as the causative bacteria of caries, and Porphyromonas gingivalis (P. gingivalis) and the like are known as the causative bacteria of periodontal disease. Has been done. Therefore, in order to maintain the oral cavity in a healthy state, it is important to suppress the number of these pathogens in the oral cavity to a low level.
従来、う蝕や歯周病の病原菌数を低下させるために、歯磨剤や洗口剤等の口腔用組成物に殺菌剤が配合されている。口腔用組成物に配合される殺菌剤は種々知られているが、ヒノキチオールは、低毒性で幅広い抗菌スペクトルを示すため、口腔用組成物に広く使用されている。従来、ヒノキチオールを含む口腔用組成物の処方について、種々提案されている。例えば、特許文献１には、口腔用組成物にヒノキチオールと共にレモングラスシトラールを配合することによって、殺菌作用を相乗的に向上させ得ることが開示されている。 Conventionally, in order to reduce the number of pathogenic bacteria of caries and periodontal disease, a bactericidal agent is blended in an oral composition such as a dentifrice and a mouthwash. Although various disinfectants to be added to oral compositions are known, hinokitiol is widely used in oral compositions because of its low toxicity and wide antibacterial spectrum. Conventionally, various formulations of oral compositions containing hinokitiol have been proposed. For example, Patent Document 1 discloses that the bactericidal action can be synergistically improved by blending lemongrass citral together with hinokitiol in an oral composition.
一方、ヒノキチオールは、水に対する溶解度が低く、口腔用組成物に配合すると、可溶化し難かったり、析出物が生成し易くなったりするという欠点がある。そこで、ヒノキチオールを含む口腔用組成物において、ヒノキチオールの溶解性を高める製剤技術の開発が求められている。 On the other hand, hinokitiol has a low solubility in water, and when blended in an oral composition, it has a drawback that it is difficult to solubilize or a precipitate is easily formed. Therefore, in the oral composition containing hinokitiol, the development of a pharmaceutical technique for enhancing the solubility of hinokitiol is required.
本発明の目的は、ヒノキチオールを含む口腔用組成物において、ヒノキチオールの溶解性を高め、ヒノキチオールによる析出物や不溶物の生成を抑制できる製剤技術を提供することである。 An object of the present invention is to provide a pharmaceutical technique capable of increasing the solubility of hinokitiol and suppressing the formation of precipitates and insoluble matter by hinokitiol in an oral composition containing hinokitiol.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、口腔用組成物において、ヒノキチオールと共に水溶性銅化合物を配合することにより、ヒノキチオールの溶解性が向上し、ヒノキチオールによる析出物や不溶物の生成を抑制できることを見出した。本発明は、かかる知見に基づいて更に検討を重ねることにより完成したものである。 As a result of diligent studies to solve the above problems, the present inventor has improved the solubility of hinokitiol by blending a water-soluble copper compound together with hinokitiol in the oral composition, and precipitates and insolubles due to hinokitiol. We have found that the production of things can be suppressed. The present invention has been completed by further studies based on such findings.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． ヒノキチオール、及び水溶性銅化合物を含有する、口腔用組成物。
項２． 前記水溶性銅化合物が、銅クロロフィリンナトリウム又はグルコン酸銅である、項１に記載の口腔用組成物。
項３． ヒノキチオールを含む口腔用組成物においてヒノキチオールの溶解性を向上させる方法であって、
口腔用組成物に、ヒノキチオール及び水溶性銅化合物を配合する、溶解性向上方法。
That is, the present invention provides the inventions of the following aspects.
Item 1. An oral composition containing hinokitiol and a water-soluble copper compound.
Item 2. Item 2. The oral composition according to Item 1, wherein the water-soluble copper compound is sodium copper chlorophyllin or copper gluconate.
Item 3. A method for improving the solubility of hinokitiol in an oral composition containing hinokitiol.
A method for improving solubility, in which hinokitiol and a water-soluble copper compound are added to an oral composition.
本発明によれば、ヒノキチオールを含む口腔用組成物において、ヒノキチオールの溶解性を高め、ヒノキチオールによる析出物や不溶物の生成を抑制することができる。 According to the present invention, in an oral composition containing hinokitiol, the solubility of hinokitiol can be enhanced and the formation of precipitates and insoluble matter due to hinokitiol can be suppressed.
１．口腔用組成物
本発明の口腔用組成物は、ヒノキチオール、及び水溶性銅化合物を含有することを特徴とする。以下、本発明の口腔用組成物について詳述する。
1. 1. Oral Composition The oral composition of the present invention is characterized by containing hinokitiol and a water-soluble copper compound. Hereinafter, the oral composition of the present invention will be described in detail.
［ヒノキチオール］
本発明の口腔用組成物はヒノキチオールを含有する。ヒノキチオールとは、殺菌作用等を有している公知の化合物である。
[Hinokitiol]
The oral composition of the present invention contains hinokitiol. Hinokitiol is a known compound having a bactericidal action and the like.
本発明において、ヒノキチオールは、天然物由来のものを使用してもよく、化学合成されたものを使用してもよい。また、本発明で使用されるヒノキチオールは、精製品又は粗精製品の別を問わず、例えば、樹木から得られたヒノキチオール含有精油を使用することもできる。 In the present invention, the hinokitiol may be derived from a natural product or chemically synthesized. Further, as the hinokitiol used in the present invention, regardless of whether it is a refined product or a crude product, for example, a hinokitiol-containing essential oil obtained from a tree can be used.
本発明の口腔用組成物におけるヒノキチオールの含有量は、口腔用組成物の種類、付与すべき殺菌作用の程度等に応じて適宜設定すればよいが、例えば、０．０００５～１重量％、好ましくは０．００５～０．８重量％、より好ましくは０．０１～０．５重量％が挙げられる。 The content of hinokithiol in the oral composition of the present invention may be appropriately set according to the type of the oral composition, the degree of bactericidal action to be imparted, and the like, and is preferably 0.0005 to 1% by weight, for example. Is 0.005 to 0.8% by weight, more preferably 0.01 to 0.5% by weight.
［水溶性銅化合物］
本発明の口腔用組成物は、ヒノキチオールに加えて、水溶性銅化合物を含有する。本発明の口腔用組成物において、水溶性銅化合物は、ヒノキチオールの溶解性を高め、ヒノキチオールによる析出物や不溶物の生成を抑制する役割を果たす。
[Water-soluble copper compound]
The oral composition of the present invention contains a water-soluble copper compound in addition to hinokitiol. In the oral composition of the present invention, the water-soluble copper compound plays a role of increasing the solubility of hinokitiol and suppressing the formation of precipitates and insoluble matter by hinokitiol.
水溶性銅化合物とは、水溶性の銅錯体及び銅塩である。水溶性の銅錯体の種類については、口腔内に適用可能であることを限度として特に制限されないが、例えば、銅クロロフィリンのアルカリ金属塩（銅クロロフィリンナトリウム等）等が挙げられる。また、水溶性の銅塩の種類については、口腔内に適用可能であることを限度として特に制限されないが、例えば、グルコン酸銅、硫酸銅、塩化銅、硝酸銅、酢酸銅、乳酸銅、酪酸銅、蟻酸銅、リン酸銅、リンゴ酸銅、コハク酸銅、マロン酸銅、マレイン酸銅等が挙げられる。 The water-soluble copper compound is a water-soluble copper complex and a copper salt. The type of the water-soluble copper complex is not particularly limited as long as it can be applied to the oral cavity, and examples thereof include an alkali metal salt of copper chlorophyllin (sodium copper chlorophyllin, etc.). The type of water-soluble copper salt is not particularly limited as long as it can be applied to the oral cavity, and for example, copper gluconate, copper sulfate, copper chloride, copper nitrate, copper acetate, copper lactate, butyric acid. Examples thereof include copper, copper formic acid, copper phosphate, copper malate, copper succinate, copper malonate, copper maleate and the like.
これらの水溶性銅化合物は、１種単独で使用してもよく、２種以上を組み合わせて使用してもよい。これらの水溶性銅化合物の中でも、ヒノキチオールの溶解性をより一層向上させるという観点から、好ましくは銅クロロフィリンのアルカリ金属塩、グルコン酸銅、より好ましくは銅クロロフィリンのアルカリ金属塩、更に好ましくは銅クロロフィリンナトリウムが挙げられる。 These water-soluble copper compounds may be used alone or in combination of two or more. Among these water-soluble copper compounds, from the viewpoint of further improving the solubility of hinokithiol, preferably an alkali metal salt of copper chlorophyllin, copper gluconate, more preferably an alkali metal salt of copper chlorophyllin, still more preferably copper chlorophyllin. Examples include sodium.
本発明の口腔用組成物における水溶性銅化合物の含有量は、口腔用組成物の種類、ヒノキチオールの含有量等に応じて適宜設定すればよいが、例えば、水溶性銅化合物の総量で０．００００５～５重量％、好ましくは０．０００１～１重量％、より好ましくは０．００５～０．５重量％、更に好ましくは０．０１～０．２重量％が挙げられる。 The content of the water-soluble copper compound in the oral composition of the present invention may be appropriately set according to the type of the oral composition, the content of hinokithiol, etc., and for example, the total amount of the water-soluble copper compound is 0. 0005 to 5% by weight, preferably 0.0001 to 1% by weight, more preferably 0.005 to 0.5% by weight, still more preferably 0.01 to 0.2% by weight.
本発明の口腔用組成物において、ヒノキチオールと水溶性銅化合物の比率については、これらの両成分の各含有量に応じて定まるが、例えば、ヒノキチオール１重量部当たり、水溶性銅化合物が総量で０．００１～１００重量部、好ましくは０．０１～１０重量部、より好ましくは０．０５～５重量部が挙げられる。 In the oral composition of the present invention, the ratio of hinokitiol to the water-soluble copper compound is determined according to the content of each of these components. For example, the total amount of the water-soluble copper compound is 0 per 1 part by weight of hinokitiol. .001 to 100 parts by weight, preferably 0.01 to 10 parts by weight, more preferably 0.05 to 5 parts by weight.
［ジメチルスルホキシド］
本発明の口腔用組成物は、前述する成分に加えて、ジメチルスルホキシドを含んでいてもよい。
[Dimethyl sulfoxide]
The oral composition of the present invention may contain dimethyl sulfoxide in addition to the above-mentioned components.
本発明の口腔用組成物にジメチルスルホキシドを含有させる場合、その含有量については、特に制限されないが、例えば、０．０１～１５重量％、好ましくは０．１～１０重量％、より好ましくは１～８重量％が挙げられる。 When dimethyl sulfoxide is contained in the oral composition of the present invention, the content thereof is not particularly limited, but is, for example, 0.01 to 15% by weight, preferably 0.1 to 10% by weight, more preferably 1. ~ 8% by weight can be mentioned.
［１価低級アルコール］
本発明の口腔用組成物は、必要に応じて、１価低級アルコールを含んでいてもよい。本発明において、１価低級アルコールとは炭素数１～５の１価アルコールを指す。
[Monohydric lower alcohol]
The oral composition of the present invention may contain a monohydric lower alcohol, if necessary. In the present invention, the monohydric lower alcohol refers to a monohydric alcohol having 1 to 5 carbon atoms.
１価低級アルコールの種類については、口腔内に適用可能であることを限度として特に制限されないが、例えば、エタノール、ｎ－プロパノール、イソプロパノール、ｎ－ブタノール、ｓｅｃ－ブタノール、ｔｅｒｔ－ブタノール、ｎ－アミルアルコール、ｓｅｃ－アミルアルコール、イソアミルアルコール、ｔｅｒｔ－アミルアルコール、ネオペンチルアルコール等が挙げられる。これらの１価低級アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 The type of monohydric lower alcohol is not particularly limited as long as it can be applied orally, but for example, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, tert-butanol, n-amyl. Examples thereof include alcohol, sec-amyl alcohol, isoamyl alcohol, tert-amyl alcohol, neopentyl alcohol and the like. These monohydric lower alcohols may be used alone or in combination of two or more.
これらの１価低級アルコールの中でも、好ましくはエタノールが挙げられる。 Among these monohydric lower alcohols, ethanol is preferable.
本発明の口腔用組成物に１価低級アルコールを含有させる場合、その含有量については、特に制限されないが、例えば、０．００１～５重量％、好ましくは０．０１～２重量％、より好ましくは０．０５～１重量％が挙げられる。 When the monohydric lower alcohol is contained in the oral composition of the present invention, the content thereof is not particularly limited, but is, for example, 0.001 to 5% by weight, preferably 0.01 to 2% by weight, more preferably. Is 0.05 to 1% by weight.
［水］
本発明の口腔用組成物は、溶媒として水を含む。本発明の口腔用組成物における水の含有量については、添加する成分を除いた残部であればよいが、例えば、３０～９９重量％、好ましくは４０～９９重量％、５０～９８重量％が挙げられる。
[water]
The oral composition of the present invention contains water as a solvent. The content of water in the oral composition of the present invention may be the balance excluding the components to be added, but is, for example, 30 to 99% by weight, preferably 40 to 99% by weight, and 50 to 98% by weight. Can be mentioned.
［その他の成分］
本発明の口腔用組成物は、前述する成分以外に、必要に応じて他の薬効成分が含まれていてもよい。このような薬効成分としては、医薬品、口腔ケア製品等に配合可能なものであることを限度として特に制限されないが、例えば、ヨウ素系殺菌成分、気管支拡張薬、鎮咳薬、去痰薬、抗炎症剤、グルコシルトランスフェラーゼ阻害剤、プラーク抑制剤、知覚過敏抑制剤、歯石予防剤、解熱鎮痛薬、抗ヒスタミン薬、殺菌剤、胃粘膜保護薬、カフェイン類、ビタミン薬、漢方薬、生薬成分等が挙げられる。
[Other ingredients]
The oral composition of the present invention may contain other medicinal ingredients in addition to the above-mentioned ingredients, if necessary. Such medicinal ingredients are not particularly limited as long as they can be blended in pharmaceutical products, oral care products, etc., but for example, iodine-based bactericidal ingredients, bronchial dilators, antitussives, expectorants, anti-inflammatory agents, etc. , Glucosyltransferase inhibitor, plaque inhibitor, hypersensitivity inhibitor, tooth stone preventive agent, antipyretic analgesic, antihistamine, bactericidal agent, gastromucosal protectant, caffeine, vitamin drug, Chinese herbal medicine, raw medicine ingredient, etc. ..
また、本発明の口腔用組成物には、所望の製剤形態にするために、基剤や添加剤が含まれていてもよい。このような基剤や添加剤としては、医薬品、口腔ケア製品等に配合可能でものであることを限度として特に制限されないが、例えば、油性成分、多価アルコール、界面活性剤、清涼化剤、防腐剤、増粘剤、香料、矯味剤、色素、消臭成分（水溶性銅化合物以外）、顔料、緩衝剤、ｐＨ調整剤等が挙げられる。 In addition, the oral composition of the present invention may contain a base or an additive in order to obtain a desired pharmaceutical form. Such bases and additives are not particularly limited as long as they can be blended in pharmaceuticals, oral care products, etc., but for example, oily components, polyhydric alcohols, surfactants, refreshing agents, preservatives, etc. Examples thereof include agents, thickeners, fragrances, flavoring agents, pigments, deodorant components (other than water-soluble copper compounds), pigments, buffers, pH adjusters and the like.
［形状・製剤形態］
本発明の口腔用組成物の形状については、特に制限されず、液状又は半固形状（ゲル状、軟膏状、ペースト状）のいずれであってもよい。
[Shape / formulation form]
The shape of the oral composition of the present invention is not particularly limited and may be liquid or semi-solid (gel, ointment, paste).
本発明の口腔用組成物の製剤形態は、口腔内に適用されて口腔内で一定時間滞留し得るものである限り制限されないが、例えば、液状歯磨剤、練歯磨剤、洗口液、口腔用スプレー（喉用のスプレー剤を含む）、含嗽剤、口中清涼剤、口腔用パスタ剤、歯肉マッサージクリーム等の口腔ケア製品が挙げられる。これらの中でも、好ましくは液状歯磨剤、練歯磨剤、洗口液、含嗽剤、より好ましくは液状歯磨剤、練歯磨剤が挙げられる。 The formulation form of the oral composition of the present invention is not limited as long as it is applied to the oral cavity and can stay in the oral cavity for a certain period of time, but for example, a liquid gingival agent, a gingival agent, a mouthwash, and an oral cavity are used. Examples include oral care products such as sprays (including throat sprays), mouthwashes, mouthwashes, oral pasta, and gingival massage creams. Among these, a liquid dentifrice, a dentifrice, a mouthwash, a mouthwash, and more preferably a liquid dentifrice and a dentifrice are mentioned.
２．ヒノキチオールの溶解性向上方法
本発明の溶解性向上方法は、ヒノキチオールを含む口腔用組成物においてヒノキチオールの溶解性を向上させる方法であって、口腔用組成物に、ヒノキチオール及び水溶性銅化合物を配合することを特徴とする。
2. 2. Method for Improving Solubility of Hinokitiol The method for improving the solubility of hinokitiol is a method for improving the solubility of hinokitiol in an oral composition containing hinokitiol, in which hinokitiol and a water-soluble copper compound are added to the oral composition. It is characterized by that.
本発明の溶解性向上方法において、使用する成分の種類や使用量、口腔用組成物の形状や製剤形態等については、前記「１．口腔用組成物」の欄に示す通りである。 The types and amounts of the components used in the method for improving the solubility of the present invention, the shape of the oral composition, the formulation form, and the like are as shown in the column of "1. Oral composition".
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
試験例１
表１に示す口腔用組成物（液状）を調製した。具体的には、ジメチルスルホキシド又はエタノールに溶解させたヒノキチオール、及び水溶性銅化合物（銅クロロフィリンナトリウム又はグルコン酸銅）を精製水に所定量添加して十分に混合することにより、口腔用組成物を調製した。
Test Example 1
The oral composition (liquid) shown in Table 1 was prepared. Specifically, a predetermined amount of hinokithiol dissolved in dimethyl sulfoxide or ethanol and a water-soluble copper compound (copper chlorophyllin sodium or copper gluconate) are added to purified water and mixed sufficiently to prepare an oral composition. Prepared.
得られた各口腔用組成物の外観を観察し、生じている析出物又は不溶物の程度を下記判定基準に従って判定し、ヒノキチオールの溶解性を評価した。
＜判定基準＞
◎：析出物又は不溶物が全く生じておらず、ヒノキチオールが完全に溶解された状態になっている。
○：僅かにだけ析出物又は不溶物が認められるが、ヒノキチオールの溶解性は改善されており、実用上問題のない状態である。
×：析出物又は不溶物が著しく認められ、ヒノキチオールの溶解性が改善されておらず、実用化できない状態である。
The appearance of each of the obtained oral compositions was observed, the degree of the resulting precipitate or insoluble matter was determined according to the following criteria, and the solubility of hinokitiol was evaluated.
<Judgment criteria>
⊚: No precipitate or insoluble matter was generated, and hinokitiol was completely dissolved.
◯: Precipitates or insoluble matter are observed only slightly, but the solubility of hinokitiol is improved and there is no problem in practical use.
X: Precipitates or insoluble matters are remarkably observed, and the solubility of hinokitiol has not been improved, so that it cannot be put into practical use.
結果を表１に示す。ヒノキチオールを含む口腔用組成物において、銅クロロフィリンナトリウム又はグルコン酸銅を含まない場合、顕著な析出物又は不溶物が認められた（比較例１及び２）。これに対して、ヒノキチオールと共に、銅クロロフィリンナトリウム又はグルコン酸銅を含む口腔用組成物では、ヒノキチオールの溶解性が向上し、析出物又は不溶物の生成が十分に抑制されていた（実施例１～５）。特に、ヒノキチオール及び銅クロロフィリンナトリウムを含む口腔用組成物では、析出物又は不溶物が全く認められず、ヒノキチオールの溶解性が顕著に向上していた（実施例１～３）。 The results are shown in Table 1. In the oral composition containing hinokitiol, when copper chlorophyllin sodium or copper gluconate was not contained, a remarkable precipitate or insoluble matter was observed (Comparative Examples 1 and 2). On the other hand, in the oral composition containing copper chlorophyllin sodium or copper gluconate together with hinokitiol, the solubility of hinokitiol was improved and the formation of precipitates or insoluble matters was sufficiently suppressed (Examples 1 to 1). 5). In particular, in the oral composition containing hinokitiol and sodium copper chlorophyllin, no precipitate or insoluble matter was observed, and the solubility of hinokitiol was significantly improved (Examples 1 to 3).
また、実施例４及び５において、グルコン酸銅を硫酸銅、塩化銅又は硝酸銅に変更した口腔用組成物を調製し、前記と同様に、ヒノキチオールの溶解性を評価したところ、析出物又は不溶物の生成が十分に抑制されており、実施例４及び５と同様の結果であった。 Further, in Examples 4 and 5, oral compositions in which copper gluconate was changed to copper sulfate, copper chloride or copper nitrate were prepared, and the solubility of hinokithiol was evaluated in the same manner as described above. The production of the substance was sufficiently suppressed, and the results were similar to those of Examples 4 and 5.
処方例
表２に示す組成の練歯磨剤、及び表３に示す組成の液状歯磨剤を調製した。これらの練歯磨剤及び液状歯磨剤は、いずれも、ヒノキチオールの溶解性が向上し、析出物又は不溶物の生成が十分に抑制できていた。
Formulation Examples A dentifrice having the composition shown in Table 2 and a liquid dentifrice having the composition shown in Table 3 were prepared. In both of these dentifrices and liquid dentifrices, the solubility of hinokitiol was improved, and the formation of precipitates or insoluble matters could be sufficiently suppressed.
Claims (3)
口腔用組成物に、ヒノキチオール及び水溶性銅化合物を配合する、溶解性向上方法。 A method for improving the solubility of hinokitiol in an oral composition containing hinokitiol.
A method for improving solubility, in which hinokitiol and a water-soluble copper compound are added to an oral composition.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213485A JP2022099621A (en) | 2020-12-23 | 2020-12-23 | Oral composition |
| CN202180086627.1A CN116634985A (en) | 2020-12-23 | 2021-12-07 | Oral composition |
| PCT/JP2021/044980 WO2022138144A1 (en) | 2020-12-23 | 2021-12-07 | Oral composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213485A JP2022099621A (en) | 2020-12-23 | 2020-12-23 | Oral composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022099621A true JP2022099621A (en) | 2022-07-05 |
Family
ID=82159680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213485A Pending JP2022099621A (en) | 2020-12-23 | 2020-12-23 | Oral composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2022099621A (en) |
| CN (1) | CN116634985A (en) |
| WO (1) | WO2022138144A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138155A (en) * | 1993-11-12 | 1995-05-30 | Otsuka Pharmaceut Co Ltd | Antimicrobial agent |
| JP2002047171A (en) * | 2000-08-01 | 2002-02-12 | Asahi Kasei Corp | Bath medicine |
| JP7127524B2 (en) * | 2018-12-18 | 2022-08-30 | ライオン株式会社 | oral products |
| JP2021031400A (en) * | 2019-08-19 | 2021-03-01 | サンスター株式会社 | Oral composition |
| JP7267872B2 (en) * | 2019-08-19 | 2023-05-02 | サンスター株式会社 | oral composition |
-
2020
- 2020-12-23 JP JP2020213485A patent/JP2022099621A/en active Pending
-
2021
- 2021-12-07 CN CN202180086627.1A patent/CN116634985A/en active Pending
- 2021-12-07 WO PCT/JP2021/044980 patent/WO2022138144A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN116634985A (en) | 2023-08-22 |
| WO2022138144A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4096241A (en) | Tooth preparations | |
| JP6381912B2 (en) | Oral composition | |
| JP2010037318A (en) | Dentifrice composition | |
| JP2979446B2 (en) | Oral composition | |
| KR101733916B1 (en) | Toothpaste comprising natural surface-active agent and the fabrication method the same | |
| JPWO2016006647A1 (en) | Oral composition | |
| JPH07501327A (en) | Antiseptic pharmaceutical composition comprising chlorhexidine and eugenol | |
| JP2020011951A (en) | Oral composition | |
| WO2022138144A1 (en) | Oral composition | |
| JP2022099622A (en) | Oral composition | |
| JP2000044467A (en) | Agent for stimulating blood flow | |
| JPH07228887A (en) | Perfume composition having enhanced refreshing feeling of 1-menthol and method for enhancing refreshing feeling of 1-menthol | |
| JP6574150B2 (en) | Oral composition | |
| JP4796700B2 (en) | Antibacterial oral or external medicine composition | |
| WO2022220044A1 (en) | Oral composition | |
| JPH09175967A (en) | Composition for oral cavity | |
| JP2022072787A (en) | Oral composition | |
| JP2022072786A (en) | Oral composition | |
| JP6249588B2 (en) | Oral composition | |
| CN109689016B (en) | Liquid oral composition | |
| JP2024066672A (en) | Oral Composition | |
| JPH02264711A (en) | Dentifrice composition | |
| WO2022092040A1 (en) | Oral composition | |
| JP2022099625A (en) | Composition for oral cavity | |
| JP6439425B2 (en) | Liquid oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |